DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Angiotensin II Blockade and Inflammation in Obesity

Information source: Virginia Polytechnic Institute and State University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Overweight; Obese; Prehypertension; Hypertension

Intervention: Olmesartan medoxomil (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Virginia Polytechnic Institute and State University

Official(s) and/or principal investigator(s):
Kevin P. Davy, Ph.D., Principal Investigator, Affiliation: Virginia Polytechnic Institute and State University

Summary

Overweight and obesity, which afflicts ~65% of the U. S. population and more than 1 billion people worldwide, increases the risk of developing hypertension. Activation of the renin angiotensin system (RAS) is an important mechanism by which obesity leads to hypertension. In addition to its vasoconstricting and sodium retaining actions, angiotensin II also has potent pro-inflammatory actions including macrophage infiltration and expression of proinflammatory cytokines in target tissues. Adipose tissue and skeletal muscle appear to be a key sites for the generation of proinflammatory cytokines. Although angiotensin II receptor blockade reduces inflammation in many tissues, the effects on adipose tissue and skeletal muscle in humans are not clear. Importantly, the chronic low grade inflammatory state that accompanies obesity complicates hypertension by contributing to insulin resistance and accelerating cardiovascular disease. Therefore, the general aim of the present proposal will be to determine the influence of angiotensin II receptor blockade on adipose tissue and skeletal muscle inflammation and its relation to improvements in insulin sensitivity, if observed, in obese hypertensive humans. To address these aims, 44 obese (BMI>30 kg/m2) hypertensive (BP>140 systolic and/or 90 diastolic) individuals (age=50-65 years) will be randomized to receive 8 weeks of either the angiotensin II receptor antagonist, olmesartan medoxomil, or no treatment in a crossover manner. Subcutaneous adipose tissue and skeletal muscle biopsies will be obtained and insulin sensitivity (intravenous glucose tolerance tests) will be assessed at baseline and following 8 weeks of each intervention. A two week washout period will separate the interventions.

Clinical Details

Official title: Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome:

CD68 Gene Expression by Immunohistochemistry of Adipose Tissue

Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18-75 years of age

- Weight stable for previous 6 months (+2. 0kg)

- Sedentary to recreationally active

- Willing to be randomized to treatment or placebo

- Verbal and written informed consent

- Approved for participation by Medical Director (Jose Rivero, M. D.)

Exclusion Criteria:

- Blood pressure outside stated range

- Diabetes or taking diabetes medications

- Total cholesterol >6. 2 mmol/L; triglycerides >4. 5 mmol/L

- Past or current ischemic heart disease, stroke, respiratory disease, endocrine or

metabolic disease, neurological disease, or hematological-oncological disease

- Evidence of renal insufficiency; GFR< 60 ml/min*

- Medications (including but not limited to antihypertensives, statins or other with

anti-inflammatory actions) or antioxidant vitamins or supplements

- Known allergy or hypersensitivity to olmesartan or any of its components

- Pregnant or planning to become pregnant

Locations and Contacts

Additional Information

Starting date: February 2009
Last updated: January 8, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017